Sun Pharmaceutical Industries, led by Managing Director Dilip Shanghvi, anticipates a high single-digit growth in consolidated revenue for FY25. The company reported consolidated revenues of ₹48,497 crore for FY24, up from ₹43,886 crore in FY23. Shanghvi mentioned that Sun Pharma is in an investment phase, focusing on product launches in the US and the expansion of its global specialty business. The firm plans to allocate 8-10% of sales to R&D. Despite potential short-term impacts on profitability, Sun Pharma aims for long-term strength. Currently, Sun Pharma leads the Indian pharmaceutical market with an 8.5% share.
Sun Pharma Projects High Single-Digit Growth for FY25
![](https://affairsace-media.s3.ap-south-1.amazonaws.com/2024/06/03111842/1679829007-9136-ezgif.com-avif-to-jpg-converter.jpg)